Antimicrobial Activity against Fusarium oxysporum f. sp. dianthi of TiO2/ZnO Thin Films under UV Irradiation: Experimental and Theoretical Study.

We deposited bare TiO2 and TiO2/ZnO thin films to study their antimicrobial capacity against Fusarium oxysporum f. sp. dianthi. The deposit of TiO2 was performed by spin coating and the ZnO thin films were deposited onto the TiO2 surface by plasma-assisted reactive evaporation technique. The characterization of the compounds was carried out by scanning electron microscopy (SEM) and powder X-ray diffraction techniques. Furthermore, density functional theory (DFT) and time-dependent DFT (TDDFT) calculations were performed to support the observed experimental results. Thus, the removal of methylene blue (MB) by adsorption and posterior photocatalytic degradation was studied. Adsorption kinetic results showed that TiO2/ZnO thin films were more efficient in MB removal than bare TiO2 thin films, and the pseudo-second-order model was suitable to describe the experimental results for TiO2/ZnO (q e = 12.9 mg/g; k 2 = 0.14 g/mg/min) and TiO2 thin films (q e = 12.0 mg/g; k 2 = 0.13 g/mg/min). Photocatalytic results under UV irradiation showed that TiO2 thin films reached 10.9% of MB photodegradation (k = 1.0 × 10-3 min-1), whereas TiO2/ZnO thin films reached 20.6% of MB photodegradation (k = 3.9 × 10-3 min-1). Both thin films reduced the photocatalytic efficiency by less than 3% after 4 photocatalytic tests. DFT study showed that the highest occupied molecular orbital-lowest unoccupied molecular orbital (HOMO-LUMO) energy gap decreases for the mixed nanoparticle system, showing its increased reactivity. Furthermore, the chemical hardness shows a lower value for the mixed system, whereas the electrophilicity index shows the biggest value, supporting the larger reactivity for the mixed nanoparticle system. Finally, the antimicrobial activity against F. oxysporum f. sp. dianthi showed that bare TiO2 reached a growth reduction of 68% while TiO2/ZnO reached a growth reduction of 90% after 250 min of UV irradiation.

Association of Abnormal Cardiac Biomarkers and Cardiovascular Complications, with Mortality in Patients with SARS-CoV-2 Infection in Latin America.

BACKGROUND: The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes. OBJECTIVE: This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America. SUBJECTS AND METHODS: The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (n = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers. RESULTS: Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer. CONCLUSIONS: In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.

Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA).

Background: The value of Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitor) therapy in individuals with heart failure with preserved EF (HFpEF) was unknown until the EMPEROR-Preserved trial. We aimed to assess the proportion of patients with HFpEF that are eligible for empagliflozin therapy within the Colombian Heart Failure Registry (RECOLFACA). Methods: RECOLFACA enrolled adult patients with a HF diagnosis during 2017-2019 from 60 medical centers in Colombia. Criteria of the EMPEROR-Preserved Trial were used to recruit participants. The main outcome was individual eligibility with N-terminal pro-B-type natriuretic peptide (NT-proBNP) criteria, while the secondary outcome was eligibility without NT-proBNP data. Results: RECOLFACA had 799 patients with HFpEF (mean age70.7 ± 13.5; 50.7 % males). According to the major selection criteria of the EMPEROR Preserved Trial, 73.7 % patients would be eligible for empagliflozin therapy initiation when considering the NT-proBNP threshold. The NT-proBNP threshold represented the main determinant of ineligibility in patients with this biomarker measure (13.6 %; n = 16). In patients without NT-proBNP data, the main reasons for exclusion were the diagnosis of symptomatic hypotension or a systolic blood pressure below 100 mmHg (7.5 %), having an eGFR < 20 ml/min/1.73 m2 (4.3 %), and haemoglobin < 9 g/dl (3.1 %). Excluding NT-proBNP criteria increased empagliflozin eligibility to 80.6 %. Conclusion: Most patients with HFpEF from RECOLFACA are potential candidates for empagliflozin therapy initiation according to the EMPEROR-Preserved trial criteria. These findings favor the utilization of SGLT-2 inhibitor medications in daily medical practice, which may further decrease morbidity and mortality in HF patients, regardless of their EF classification.

EFFECTIVENESS OF DORSAL ROOT GANGLION STIMULATION IN CHRONIC PAIN MANAGEMENT: A SYSTEMATIC REVIEW.

OBJECTIVE: This systematic review aims to determine the effectiveness of Dorsal Root Ganglion Stimulation (DRGS) in chronic pain management. MATERIALS AND METHODS: In 2023, a comprehensive systematic review was undertaken utilizing various electronic databases, employing MeSH terms and free search terms tailored to the study's aims. This review included primary research such as cohorts, case-control studies, and clinical trials, all focusing on the efficacy of DRGS in treating various chronic pain conditions. Non-human or animal studies were omitted from the selection process. A review of study quality was conducted, followed by meticulous analysis of the findings to synthesize the evidence. This review represents the most current research, with updates extending to 2024. A total of 400 articles were reviewed. 29 articles were included in our review after meticulous screening. RESULTS: Twenty-nine articles published in the last five years meeting selection criteria were identified, encompassing patients with various diagnoses warranting the use of DRGS beyond CRPS. Additionally, the analysis includes different outcome measurement tools, emphasizing improvements in pain management, functionality, and quality of life. Finally, common complications such as surgical site infection and issues with electrodes are highlighted. CONCLUSIONS: This systematic review affirms the effectiveness of DRGS therapy in managing diverse chronic pain conditions, highlighting improvements in quality of life, functionality, and mood states, making it a viable alternative for patients unresponsive to traditional treatments.

Horizontal Gaze Assessment: An Extensive Narrative Review.

OBJECTIVE: Bipedalism was a significant milestone in the evolutionary development of Homo sapiens sapiens, influencing neocortical evolution and subsequent behavioral changes. Coordinated visual and sensory inputs are crucial for posture, environmental interaction, and surgical planning, with horizontal gaze being a pivotal parameter. This narrative review aims to explore various geometric measures used to assess horizontal gaze in patients, highlighting their applications in surgical planning. METHODS: A literature review was conducted in indexed databases using Mesh terms like "Cervical Vertebrae" and "Visual Fields" along with keywords such as "horizontal gaze" and "sagittal spine parameters." Among 477 initially identified articles, 41 were selected for inclusion after rigorous filtering. RESULTS: The most recognized method for assessing horizontal gaze is the Chin Brow Vertical Angle (CBVA), initially described in patients with ankylosing spondylitis. Clinical photography is employed as a tool for CBVA calculation, while other measures like McGregor slope and Slope of the Line of Sight have been considered as alternatives to CBVA. Each method presents its unique advantages and limitations. CONCLUSIONS: This review highlights the need for further research into horizontal gaze measurement methods. Developing novel approaches to determine horizontal gaze can significantly enhance surgical planning and, consequently, improve patient outcomes. The ongoing exploration of these geometric measures offers promising prospects for advancing the field and optimizing patient care.

The safety profile of mesenchymal stem cell therapy administered through intrathecal injections for treating neurological disorders: a systematic review and meta-analysis of randomised controlled trials.

BACKGROUND: Based on previous in vivo studies and human trials, intrathecal cell delivery is a safe and relevant therapeutic tool for improving patient's quality of life with neurological conditions. We aimed to characterise the safety profile of intrathecally delivered Mesenchymal stem cells (MSCs). METHODS: Ovid MEDLINE, Embase, Scopus, Cochrane Library, KCI-Korean Journal Database, and Web of Science. Databases were searched from their inception until April 13, 2023. Randomised Controlled Trials (RCTs) that compared intrathecal delivery of MSCs to controls in adult populations were included. Adverse events (AEs) were pooled and meta-analysed using DerSimonian-Laird random effects models with a correction factor 0.5 added to studies with zero count cells. Pooled AEs were described using Risk ratio (RR) and 95% confidence intervals (95% CI). Then, a random-effects meta-regress model on study-level summary data was performed to explore the relationship between the occurrence of AEs and covariates thought to modify the overall effect estimate. Finally, publication bias was assessed. RESULTS: 303 records were reviewed, and nine RCTs met the inclusion criteria and were included in the quantitative synthesis (n = 540 patients). MSCs delivered intrathecally, as compared to controls, were associated with an increased probability of AEs of musculoskeletal and connective tissue disorders (categorised by Common Terminology Criteria for Adverse Events-CTCAE version 5.0) (RR: 1.61, 95% CI 1.19-2.19, I2 = 0%). The random-effects meta-regress model suggested that fresh MSCs increased the probability of occurrence of AEs compared to cryopreserved MSCs (RR: 1.554; p-value = 0.048; 95% CI 1.004-2.404), and the multiple-dose, decreased the probability of AEs by 36% compared to single doses (RR: 0.644; p-value = 0.048; 95% CI 0.416-0.996); however, univariate random effects meta-regression models revealed a not significant association between the occurrence of AEs from MSCs intrathecal delivery and each covariate. CONCLUSIONS: Intrathecal delivery of MSCs was associated with a slight increase in AEs associated with musculoskeletal and connective tissue disorders, albeit without serious AEs. We conclude that intrathecal MSCs delivery is safe for patients with neurological conditions. However, further high-quality, large-scale RCTs are needed to confirm these findings.

Multizonal observational study conducted by clinical practitioners on Repatha® use in patients with hyperlipidemia (ZERBINI): Colombian results / Estudio Observacional Multizonal realizado por Médicos Clínicos sobre el Uso de Repatha® en Pacientes con Hiperlipidemia (ZERBINI): resultados colombianos

Background Cardiovascular disease (CVD) represents the primary cause of death and disability globally, with elevated cholesterol as one of the leading risk factors for CVD. We describe the clinical characteristics, treatment patterns, and effectiveness of evolocumab in treating hyperlipidemia. Methods Observational study conducted through a chart review of patients with hyperlipidemia receiving evolocumab as part of clinical management in Colombia. Results This study included 115 patients treated with evolocumab. A total of 101 patients (87.8%) had a history of CVD, 13 (11.3%) familial hypercholesterolemia (FH), and 23 (20%) type 2 diabetes. Thirty-nine patients reported intolerance to any statin (33.9%). The median value of LDL-C before initiation of evolocumab was 147mg/dL (IQR: 122.5–183.7mg/dL). Within the first 3 months of treatment, LDL-C value dropped to a median value of 53mg/dL (IQR: 34.0–95.5mg/dL), showing a reduction of 63.9%. The median LDL-C values remained below 45mg/dL until the end of follow-up. Among the patients with available data, up to 61% achieved an LDL-C level below 55mg/dL at the 10–12-month follow-up. A total of 72% of patients were persistent with treatment. Safety results showed a low frequency of hospitalizations (≤2%) and treatment-emergent adverse drug reactions (5.2%). No serious adverse events were reported. Conclusions Evolocumab was associated with reductions in LDL-C levels, with a relative decrease of 63.9% within the first 3 months of treatment. Low rates of interruptions due to adverse events and adequate medication persistence was reported. (AU)

Antecedentes Las enfermedades cardiovasculares (ECV) representan la principal causa de muerte y discapacidad en todo el mundo, siendo el colesterol elevado uno de los principales factores de riesgo de ECV. El presente estudio describe las características clínicas, patrones de tratamiento y la efectividad de evolocumab en el tratamiento de la hiperlipidemia. Métodos Estudio observacional de revisión de historias clínicas de pacientes con hiperlipidemia que reciben evolocumab como parte del manejo clínico en Colombia. Resultados Se incluyeron 115 pacientes tratados con evolocumab. Un total de 101 pacientes (87,8%) presentaron antecedentes de ECV, 13 (11,3%) de hipercolesterolemia familiar y 23 (20%) de diabetes tipo 2. De los pacientes estudiados, 39% declararon intolerancia a alguna estatina (33,9%). La mediana de C-LDL antes del inicio de evolocumab fue de 147mg/dL (IQR: 122,5-183,7mg/dL). En los primeros tres meses de tratamiento, el valor de C-LDL descendió a 53mg/dL (IQR: 34,0-95,5mg/dL), siendo una reducción de 63,9%. La mediana de C-LDL se mantuvo por debajo de 45mg/dL hasta el final del seguimiento. Entre los pacientes con datos disponibles, hasta 61% alcanzó un nivel de LDL-C inferior a 55mg/dL en el seguimiento de 10-12 meses. De los pacientes analizados, 72% fue persistente al tratamiento. Los resultados de seguridad mostraron una baja frecuencia de hospitalizaciones (≤2%) y de reacciones adversas relacionadas al tratamiento (5,2%). No se notificaron acontecimientos adversos graves. Conclusiones Evolocumab se asoció con reducciones en los niveles de C-LDL, con una disminución relativa de 63,9% en los primeros tres meses de tratamiento. Se reportaron bajas tasas de interrupciones por eventos adversos y adecuada persistencia a la medicación. (AU)

Excess degassing drives long-term volcanic unrest at Nevado del Ruiz.

This study combines volcanic gas compositions, SO2 flux and satellite thermal data collected at Nevado del Ruiz between 2018 and 2021. We find the Nevado del Ruiz plume to have exhibited relatively steady, high CO2 compositions (avg. CO2/ST ratios of 5.4 ± 1.9) throughout. Our degassing models support that the CO2/ST ratio variability derives from volatile exsolution from andesitic magma stored in the 1-4 km depth range. Separate ascent of CO2-rich gas bubbles through shallow (< 1 km depth), viscous, conduit resident magma causes the observed excess degassing. We infer that degassing of ~ 974 mm3 of shallow (1-4 km) stored magma has sourced the elevated SO2 degassing recorded during 2018-2021 (average flux ~ 1548 t/d). Of this, only < 1 mm3 of magma have been erupted through dome extrusion, highlighting a large imbalance between erupted and degassed magma. Escalating deep CO2 gas flushing, combined with the disruption of passive degassing, through sudden accumulation and pressurization of bubbles due to lithostatic pressure, may accelerate volcanic unrest and eventually lead to a major eruption.

Multizonal observational study conducted by clinical practitioners on Repatha® use in patients with hyperlipidemia (ZERBINI): Colombian results.

BACKGROUND: Cardiovascular disease (CVD) represents the primary cause of death and disability globally, with elevated cholesterol as one of the leading risk factors for CVD. We describe the clinical characteristics, treatment patterns, and effectiveness of evolocumab in treating hyperlipidemia. METHODS: Observational study conducted through a chart review of patients with hyperlipidemia receiving evolocumab as part of clinical management in Colombia. RESULTS: This study included 115 patients treated with evolocumab. A total of 101 patients (87.8%) had a history of CVD, 13 (11.3%) familial hypercholesterolemia (FH), and 23 (20%) type 2 diabetes. Thirty-nine patients reported intolerance to any statin (33.9%). The median value of LDL-C before initiation of evolocumab was 147mg/dL (IQR: 122.5-183.7mg/dL). Within the first 3 months of treatment, LDL-C value dropped to a median value of 53mg/dL (IQR: 34.0-95.5mg/dL), showing a reduction of 63.9%. The median LDL-C values remained below 45mg/dL until the end of follow-up. Among the patients with available data, up to 61% achieved an LDL-C level below 55mg/dL at the 10-12-month follow-up. A total of 72% of patients were persistent with treatment. Safety results showed a low frequency of hospitalizations (≤2%) and treatment-emergent adverse drug reactions (5.2%). No serious adverse events were reported. CONCLUSIONS: Evolocumab was associated with reductions in LDL-C levels, with a relative decrease of 63.9% within the first 3 months of treatment. Low rates of interruptions due to adverse events and adequate medication persistence was reported.

Characterization of Achalasia Subtypes Based on High-Resolution Manometry in Patients at a Reference Hospital in Colombia

Introduction: Limited information is available regarding the clinical and manometric characteristics of different subtypes of achalasia. This study aims to describe these characteristics in patients treated at a prominent hospital in Colombia. Methods: This descriptive observational study included patients diagnosed with achalasia using high-resolution esophageal manometry at Hospital Universitario San Ignacio in Bogotá, Colombia, between 2016 and 2020. We documented the clinical manifestations, manometric findings, treatment approaches, and response to treatment based on the subtype of achalasia. Results: A total of 87 patients were enrolled, with a median age of 51 years, and 56.4% of them were female. The majority had type II achalasia (78.1%), followed by type I (16%) and type III (5.7%). All patients presented with dysphagia, 40.2% experienced chest pain, and 27.6% had gastroesophageal reflux. The clinical parameters, including integrated relaxation pressure value (IRP; median: 24 mmHg, interquartile range [IQR]: 19-33), upper esophageal sphincter pressure (UES; median: 63 mmHg, IQR: 46-98), and lower esophageal sphincter pressure (LES; median: 34 mm Hg, IQR: 26-45), were similar across the different subtypes. Esophageal clearance was incomplete in all patients. Among the 35 patients who received intervention, Heller's myotomy was the most commonly employed procedure (68.5%), followed by esophageal dilation (28.6%). All patients experienced symptomatic improvement, with a median pre-treatment Eckardt score of 5 (IQR: 5-6) and a post-treatment score of 1 (IQR: 1-2). Conclusions: Type II achalasia is the most prevalent subtype. The clinical and manometric findings, as well as treatment response, exhibit similarities among the different subtypes of achalasia. In Colombia, the outcomes of this condition align with those reported in other parts of the world.

Introducción: existe información limitada sobre las características clínicas y manométricas de los diferentes subtipos de acalasia. Este estudio describe dichas características en pacientes manejados en un hospital de referencia en Colombia. Método: estudio descriptivo observacional que incluye a pacientes con diagnóstico de acalasia por manometría esofágica de alta resolución manejados en el Hospital Universitario San Ignacio de Bogotá, Colombia, entre 2016 y 2020. Se describen las manifestaciones clínicas, hallazgos manométricos, tratamiento utilizado y respuesta al mismo según el subtipo de acalasia. Resultados: se incluyeron a 87 pacientes (mediana de edad: 51 años, 56,4% mujeres). La mayoría de tipo II (78,1%), seguido por tipo I (16%) y tipo III (5,7%). Todos presentaron disfagia, 40,2% dolor torácico y 27,6% reflujo gastroesofágico. La clínica y los valores del integral de presión de relajación (IRP; mediana: 24 mm Hg, rango intercuartílico [RIC]: 19-33), presión del esfínter esofágico superior (EES; mediana: 63 mm Hg, RIC: 46-98) y presión del esfínter esofágico inferior (EEI; mediana: 34 mm Hg, RIC: 26-45) fueron similares en los diferentes subtipos. El aclaramiento esofágico fue incompleto en todos los pacientes. Entre 35 pacientes que recibieron manejo intervencionista, la miotomía de Heller fue la intervención más utilizada (68,5%), seguido por la dilatación esofágica (28,6%). La totalidad de estos pacientes presentó una mejoría sintomática con la mediana de Eckardt pretratamiento de 5 (RIC: 5-6) y postratamiento de 1 (RIC: 1-2). Conclusiones: la acalasia tipo II es la más común. La clínica y los hallazgos manométricos y respuesta a tratamiento son similares entre los subtipos de acalasia. En Colombia, esta entidad se comporta de forma similar a lo reportado en otras partes del mundo.

Financial feasibility of end-user designed rainwater harvesting and greywater reuse systems for high water use households.

Water availability pressures, competing end-uses and sewers at capacity are all drivers for change in urban water management. Rainwater harvesting (RWH) and greywater reuse (GWR) systems constitute alternatives to reduce drinking water usage and in the case of RWH, reduce roof runoff entering sewers. Despite the increasing popularity of installations in commercial buildings, RWH and GWR technologies at a household scale have proved less popular, across a range of global contexts. For systems designed from the top-down, this is often due to the lack of a favourable cost-benefit (where subsidies are unavailable), though few studies have focused on performing full capital and operational financial assessments, particularly in high water consumption households. Using a bottom-up design approach, based on a questionnaire survey with 35 households in a residential complex in Bucaramanga, Colombia, this article considers the initial financial feasibility of three RWH and GWR system configurations proposed for high water using households (equivalent to >203 L per capita per day). A full capital and operational financial assessment was performed at a more detailed level for the most viable design using historic rainfall data. For the selected configuration ('Alt 2'), the estimated potable water saving was 44% (equivalent to 131 m3/year) with a rate of return on investment of 6.5% and an estimated payback period of 23 years. As an initial end-user-driven design exercise, these results are promising and constitute a starting point for facilitating such approaches to urban water management at the household scale.

El discreto encanto de los medicamentos / The discreet charm of drugs

El presente artículo es un resumen de un grupo de conferencias sobre la industria farmacéutica mundial ofrecidas entre 2010 y 2013 en diferentes foros nacionales e internacionales. El comportamiento de la producción y consumo de medicamentos en el mundo, teniendo en cuenta que se trata de un bien social que se utiliza para prevenir enfermedades y restablecer la salud del ser humano, ofrece un panorama extraño en relación con las reales necesidades de la población. Se analiza cuáles son los elementos implicados en ese comportamiento. Comienza con una caracterización de la industria farmacéutica mundial contemporánea y analiza tres aspectos que considera están relacionadas con estos resultados: la investigación médico-farmacéutica, la promoción e información médica y el funcionamiento de las agencias reguladoras nacionales de medicamentos. La industria farmacéutica mundial ha aportado enormes ventajas al tratamiento de las enfermedades. Es un hecho irrefutable, pero la Gran Pharma no es una industria cualquiera y requiere ser rentable. La globalización y el neoliberalismo han creado patrones de motivación y conducta basados fundamentalmente en los intereses del mercado. Debemos estar alertas en el futuro. Este nuevo siglo introduce nuevos retos a los pueblos, sus gobiernos y a la Gran Pharma en relación con la salud y la enfermedad y su enfrentamiento(AU)

This article summarized a group of lectures on the world drug industry delivered from 2010 to 2013 in a number of national and international fora. Taking into account that a pharmaceutical is a social asset used to prevent diseases and recover human health, the behavior of the drug production and consumption worldwide shows a awkward overview in terms of the real needs of the population. An analysis was made on the elements involved in such behavior, beginning with a characterization of the world current drug industry and analyzing three aspects related to the results: medical-drug research, medical promotion and information and operation of the national drug regulatory agencies. The world drug industry has provided huge benefits for the treatment of diseases and this is an undeniable fact; however, the Big Pharma needs to be profitable. Globalization and neoliberalism have created patterns of incentives and behaviors mainly based on the market interests. We should be aware of that in the future. This new century poses new challenges for the peoples, their governments and for the Big Pharma in terms of health, disease and how to face it(AU)

El discreto encanto de los medicamentos / The discreet charm of drugs

El presente artículo es un resumen de un grupo de conferencias sobre la industria farmacéutica mundial ofrecidas entre 2010 y 2013 en diferentes foros nacionales e internacionales. El comportamiento de la producción y consumo de medicamentos en el mundo, teniendo en cuenta que se trata de un bien social que se utiliza para prevenir enfermedades y restablecer la salud del ser humano, ofrece un panorama extraño en relación con las reales necesidades de la población. Se analiza cuáles son los elementos implicados en ese comportamiento. Comienza con una caracterización de la industria farmacéutica mundial contemporánea y analiza tres aspectos que considera están relacionadas con estos resultados: la investigación médico-farmacéutica, la promoción e información médica y el funcionamiento de las agencias reguladoras nacionales de medicamentos. La industria farmacéutica mundial ha aportado enormes ventajas al tratamiento de las enfermedades. Es un hecho irrefutable, pero la Gran Pharma no es una industria cualquiera y requiere ser rentable. La globalización y el neoliberalismo han creado patrones de motivación y conducta basados fundamentalmente en los intereses del mercado. Debemos estar alertas en el futuro. Este nuevo siglo introduce nuevos retos a los pueblos, sus gobiernos y a la Gran Pharma en relación con la salud y la enfermedad y su enfrentamiento(AU)

This article summarized a group of lectures on the world drug industry delivered from 2010 to 2013 in a number of national and international fora. Taking into account that a pharmaceutical is a social asset used to prevent diseases and recover human health, the behavior of the drug production and consumption worldwide shows a awkward overview in terms of the real needs of the population. An analysis was made on the elements involved in such behavior, beginning with a characterization of the world current drug industry and analyzing three aspects related to the results: medical-drug research, medical promotion and information and operation of the national drug regulatory agencies. The world drug industry has provided huge benefits for the treatment of diseases and this is an undeniable fact; however, the Big Pharma needs to be profitable. Globalization and neoliberalism have created patterns of incentives and behaviors mainly based on the market interests. We should be aware of that in the future. This new century poses new challenges for the peoples, their governments and for the Big Pharma in terms of health, disease and how to face it(AU)

Farmacoepidemiología uso racional de medicamentos / Pharmacoepidemiology rational drug use

El presente texto es el resultado del esfuerzo de un grupo de especialistas del Centro para el Desarrollo de la Farmacoepidemiología del Ministerio de Salud Pública de Cuba, para proporcionar a los interesados en el aprendizaje de la Farmacoepidemiología una bibliografía mínima e imprescindible acerca de los temas esenciales de esta disciplina. No existe un hecho similar en el país. Los temas abordados representan un trabajo de revisión, síntesis y aporte de los diferentes autores a cada uno de estos. No es una obra terminada, ni pretende ser un libro de referencia; pudiera ser quizás el embrión de un futuro libro sobre Farmacoepidemiología cubano, que entonces podría aspirar a un texto fundacional de esta actividad en Cuba.

Importancia de la actualización farmacoepidemiológica en la Atención Primaria de Salud / Importance of pharmacoepidemiology updated in Primary Health Attention

La calidad en las atención médica requiere la continua actualización de conocimientos en los diversos componentes de la práctica en general y de la intervención farmacológica en particular; la aparición de nuevos fármacos y de nuevas indicaciones de los ya existentes, el aumento del número de pacientes polimedicados y la necesidad de conocer las potenciales interacciones entre estos, son factores esenciales para una adecuada prescripción farmacológica...

Quality in health care requires continuous updating of knowledge in the various components of the practice in general and in particular pharmacological intervention, the emergence of new drugs and new indications for existing ones, increasing the number of patients with polypharmacy and the need to understand the potential interactions between these, is essential for proper drug prescriptions...